Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations
Keywords:TKI EGFR, Gefitinib, Erlotinib, Afatinib, NSCLC
Background: The use of TKI generation 1 (Gefitinib, Erlotinib) and Generation 2 (Afatinib) has become the
standard therapy for JPIC pulmonary adenocarcinoma type with positive EGFR gene mutations.
Objective: to analyze the comparison of the efficacy of TKI generation 1 and 2 in NSCLC patients with
positive EGFR mutations.
Methods: The design of this study used a retrospective in which the participants who received EGFR therapy
for TKI generations 1 and 2 were compared its efficacy. Data collected included health-related quality of life
(HRQOL), body weight, performance status (PS), Response Evaluation Criteria in Solid Tumors (RECIST)
of thoracic CT, Common Terminology Criteria for Adverse Events (CTCAE), progression free survival
(PFS) and overall survival (OS). The statistical analysis used was the independent t test, Mann Whitney test,
or Kruskal Wallis test with p <0.05.
Results: Most of the participants’ quality of life scores did not change before and after therapy, where the
EQ5D value was 67.5% (group 1 = 60.6%; Group 2 = 94.1%; p = 0.806). The participant’s weight decreased
by 49.5% (group 1 = 45.9%; group 2 = 60.0%; p = 0.658) and the participant’s PS was stable (group 1 =
29.4%; group 2 = 50.0%; p = 0.014). The RECIST value of the participant was progressive disease 51.0% (p
= 0.338). CTCAE differed in stomatitis (p <0.001), paronychia (p <0.001), and diarrhea (p <0.001). There
was no significant difference between the first and second groups in the PFS (p = 0.197) and OS (p = 0.740)
Conclusion: EGFR therapy for TKI generations 1 and 2 have almost the same efficacy, in which there is no
significant difference in the quality of life of the participants.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions